Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Alana TH Nguyen, MD, PhD
Weill Medical College of Cornell University
Principal Investigator - Andrés Muñoz, MD, PhD
Hospital Gregorio-Marañon
Principal Investigator - Arjun Mittra, MD
Martha Morehouse Tower
Principal Investigator - Berta Laquente, MD. PhD
Hospital Duran i Reynals (ICO)
Principal Investigator - Carmen Guillén-Ponce, MD, PhD
Hospital Universitario Ramon y Cajal
Principal Investigator - Christopher Nevala-Plagemann, MD
Hunstman Cancer Institute, University of Utah
Principal Investigator - Eva Martinez de Castro, MD, PhD
Hospital Universitario Marqués de Valdecilla
Principal Investigator - Inmaculada Gallego, MD, PhD
Hospitales Universitarios Virgen del Rocío
Principal Investigator - Mireya Cazorla, MD, PhD
Hospital Universitario Virgen de la Victoria
Principal Investigator - Miriam Lobo, MD, PhD
Hospital General Universitario de Valencia
Principal Investigator - Roberto Pazo, MD, PhD
Hospital Miguel Servet
Principal Investigator - Rocío García, MD, PhD
Hospital Universtario 12 de octubre
Principal Investigator - Tara E Seery, MD
Hoag Memorial Hospital Presbyterian
Principal Investigator - Teresa Macarulla, Md, PhD
Hospital Vall d'Hebron
Principal Investigator - Vivek R Sharma, MD, FACP
University of Louisville, Brown Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hospital Universitario Virgen del Rocío
Seville, Andalusia, Spain
- Hospital Duran I Reynals (ico)
L'Hospitalet de Llobregat, Barcelona, Spain
- Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, Spain
- Hospital Universitari Vall D'Hebron
Barcelona, Spain
- Hospital Gregorio Marañon
Madrid, Spain
- Hospital Universitario 12 de Octubre
Madrid, Spain
- Hospital Universitario Ramon Y Cajal
Madrid, Spain
- Hospital Universitario Virgen de la Victoria
Málaga, Spain
- Hospital General Univesitario de Valencia
Valencia, Spain
- Hospital Miguel Servet
Zaragoza, Spain
- Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
- University of California - Davis Cancer Center
Sacramento, California, United States
- University of Louisville - Brown Cancer Center
Louisville, Kentucky, United States
- Weill Cornell Medical Center
New York, New York, United States
- Martha Morehouse Tower
Columbus, Ohio, United States
- Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, United States
- Virginia Cancer Specialists
Fairfax, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 10 Jan 2023
- Primary completion
- 28 Mar 2025
- Completion
- 28 Mar 2025
- Last update posted
- 16 Apr 2025
- Registered enrollment
- 112
- Registry id
- NCT05673811
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.